ASTRO

This page includes the latest news from the American Society of Radiation Oncology (ASTRO), including news and video coverage from the society's annual meeting. ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologist, physicists, radiation therapists, dosimetrists and other healthcare professionals who specialize in treating patients with radiation therapy. 

stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017

The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of...

News | Image Guided Radiation Therapy (IGRT) | May 24, 2017

May 24, 2017 — The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as...

ASTRO's 59th Annual Meeting Will Explore Art and Science of Radiation Oncology
News | Radiation Therapy | May 19, 2017

May 19, 2017 — Registration has opened for the 59th Annual Meeting of the American Society for Radiation Oncology (...

Proton Monte Carlo Dose Calculation Now Part of RayStation Treatment Planning
News | Treatment Planning | May 15, 2017

May 15, 2017 — RaySearch demonstrated a new Monte Carlo dose planning feature for...

Accuray, CyberKnife system, SBRT, long-term disease control, prostate cancer, ASCO GU study
News | Radiation Therapy | February 17, 2017

February 17, 2017 — Accuray Inc. recently announced data from a prospective, Phase II, 17-center study which showed...

radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017

February 6, 2017 — A study published in the February issue of...

Sponsored Content | Videos | Radiation Oncology | January 05, 2017

Join Chris Toth, president, Oncology Systems Americas, for a look at Varian’s new product introductions and major...

Sponsored Content | Videos | Quality Assurance (QA) | December 20, 2016

Learn more about myQA, IBA’s unique platform that connects QA applications, people, and know-how through a central...

Somatom Confidence RT Pro, RT, radiation therapy, treatment planning
Technology | Treatment Planning | December 20, 2016

December 20, 2016 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Siemens’ Somatom...

Sponsored Content | Videos | Radiation Therapy | November 18, 2016

Accuray recently unveiled the company’s newest innovation, the Radixact Treatment Delivery System, a uniquely smart...

IBA, proton therapy, 50,000 patients treated, milestone
News | Proton Therapy | October 28, 2016

October 27, 2016 — IBA announced in September that 50,000 patients have been treated by clinical partners using IBA’...

Augmenix, SpaceOAR System, prostate cancer, three-year clinical data results, ASTRO 2016
News | Prostate Cancer | October 27, 2016

October 27, 2016 — Augmenix Inc. announced the three-year results from the SpaceOAR System...

RaySearch Labs, RayStation treatment planning system, RayCare oncology information system, University Medical Center Groningen, UMCG, Netherlands, radiation therapy
News | Treatment Planning | October 27, 2016

October 27, 2016 — University Medical Center Groningen (UMCG) in the Netherlands has selected RayStation as its...

News | Radiation Therapy | October 25, 2016

October 25, 2016 — Dicerna Pharmaceuticals Inc. announced in September that the company will focus its resources on...

intermediate-risk prostate cancer, brachytherapy versus external beam therapy, radiation therapy, RT, ASTRO 2016
News | Brachytherapy Systems | October 25, 2016

October 25, 2016 — For men with intermediate-risk...

non-small-cell lung cancer, NSCLC, SBRT, stereotactic body radiation therapy, Roswell Park study, ASTRO 2016, dose
News | Radiation Therapy | October 25, 2016

October 25, 2016 — Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of...

IBA, Philips, Ambient Experience, proton therapy, Proteus One, Proteus Plus, ASTRO 2016
News | Radiation Therapy | October 19, 2016

October 19, 2016 — IBA (Ion Beam Applications SA) and Philips announced in September the launch of a dedicated...

stereotactic radiosurgery, EGFR-mutant non-small cell lung cancer, NSCLC, brain metastases, Yale Cancer Center analysis, ASTRO 2016
News | Radiation Therapy | October 19, 2016

October 19, 2016 — A Yale Cancer Center team completed a multi-institutional analysis of treatment options for...

intensity modulated radiation therapy outcomes, IMRT, head and neck cancers, facility volume, ASTRO 2016
News | Radiation Therapy | October 18, 2016

October 18, 2016 — The association between provider case volume and outcomes has long been suggested in cancer care...